Discovery and identification of potential biomarkers of papillary thyroid carcinoma

Fan, Yuxia; Shi, Linan; Liu, Qiu-liang; Dong, Rui; Zhang, Qian; Yang, Shaobo; Fan, Yun; Yang, Heying; Wu, Peng; Yu, Jian; Zheng, Shu; Yang, Fuquan; Wang, Jiaxiang

doi:10.1186/1476-4598-8-79

Cited by 72 publications

(66 citation statements)

References 23 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with these findings, APOC1 has been reported to be a promising serum marker for the diagnosis and treatment of multiple cancers, such as gastric cancer,25 pancreatic cancer,26 colorectal cancer,27 thyroid carcinoma,28 and non‐small cell lung cancer 29…”

Section: Discussionsupporting

confidence: 55%

Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Sun

Yang

et al. 2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Here, we aimed to investigate the carcinogenic effects of apolipoprotein C1 (APOC1) in prostate cancer (PCa). APOC1 expression was evaluated in PCa and normal prostate specimens, and lentivirus‐mediated RNA interference was used to knockdown APOC1 in DU145 cells. The effects of APOC1 silencing on cell proliferation, cell cycle arrest, and apoptosis were assessed. APOC1 expression was much higher in PCa tissues than in normal tissues. Moreover, APOC1 silencing inhibited cell proliferation and colony formation, arrested cell cycle progression, and enhanced apoptosis in DU145 cells. Additionally, APOC1 silencing decreased survivin, phospho‐Rb, and p21 levels and increased cleaved caspase‐3 expression. These data supported the procarcinogenic effects of APOC1 in the pathogenesis of PCa and suggested that targeting APOC1 may have applications in the treatment of PCa.

show abstract

Section: Discussionsupporting

confidence: 55%

Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Sun

Yang

et al. 2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…Apolipoprotein C-III-containing HDL may play a key role in the prevention of apolipoprotein C-III-induced hypertriglyceridemia (30). Recently, SELDI-TOF (surface-enhanced laser desorption ionization time of flight) analysis suggests a link between an ion species at m∕z 8,697 of apolipoprotein C-III and papillary thyroid carcinoma (31). However, SELDI-TOF is a low-resolution technique, requires off-line LC purification, and has shown limited utility in biomarker development (32).…”

Section: Resultsmentioning

confidence: 99%

Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry

Mazur¹,

Cardasis²,

Spellman³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Top-down mass spectrometry holds tremendous potential for the characterization and quantification of intact proteins, including individual protein isoforms and specific posttranslationally modified forms. This technique does not require antibody reagents and thus offers a rapid path for assay development with increased specificity based on the amino acid sequence. Top-down MS is efficient whereby intact protein mass measurement, purification by mass separation, dissociation, and measurement of product ions with ppm mass accuracy occurs on the seconds to minutes time scale. Moreover, as the analysis is based on the accurate measurement of an intact protein, top-down mass spectrometry opens a research paradigm to perform quantitative analysis of "unknown" proteins that differ in accurate mass. As a proof of concept, we have applied differential mass spectrometry (dMS) to the top-down analysis of apolipoproteins isolated from human HDL 3 . The protein species at 9415.45 Da demonstrates an average fold change of 4.7 (p-value 0.017) and was identified as an O-glycosylated form of apolipoprotein C-III [NANA-ð2 → 3Þ-Gal-βð1 → 3Þ-GalNAc, þ656.2037 Da], a protein associated with coronary artery disease. This work demonstrates the utility of top-down dMS for quantitative analysis of intact protein mixtures and holds potential for facilitating a better understanding of HDL biology and complex biological systems at the protein level.quantitative proteomics | Fourier-transfrom mass spectrometry | electron transfer dissociation | top-down proteomics | posttranslational modifications

show abstract

“…The peak at 3972 Da was compared to the identified ITIH4 by Villanueva et al and found to be increased in the sera of prostate and bladder cancer patients (27). Protein peaks at 6630 and 6629 Da were identified as apolipoprotein C-I in the sera of patients with papillary thyroid carcinoma by Fan et al (28) and sera of colorectal cancer patients by Ward et al (29). The peak at 6429 Da has not yet been identified but was described as a putative biomarker in lung cancer by Yang et al (30).…”

Section: Discussionmentioning

confidence: 99%

Serum proteome profiling of primary breast cancer indicates a specific biomarker profile

Böhm

Keller²,

Wehrwein³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Non-invasive biomarkers for early breast cancer detection are urgently needed, as the risk of recurrent morbidity and mortality is closely related to the stage of the disease at the time of primary surgery. Currently, there are no established clinical biomarkers for breast cancer. Evaluation of protein expression patterns in body fluids using proteomic technologies can be used to discover new biomarkers for the detection of breast cancer. The aim of this study was to identify a biomarker signature identifying primary non-metastatic breast cancer and healthy controls. We screened 91 serum samples including 45 breast cancer patients and 46 healthy women using a proteomic approach. We found 14 biomarkers whose combination detects breast cancer patients from non-cancer controls with a sensitivity of 89% and specificity of 67%. Five biomarkers were comparable with previously identified proteins from published data using similar approaches. This biomarker panel allows accurate discrimination between breast cancer and healthy individuals. In addition, it could distinguish subgroups of breast cancer based on patterns of several specific biomarkers. Further validation of biomarkers could potentially facilitate the early diagnosis of breast cancer as an aid to imaging diagnostics.

show abstract

Discovery and identification of potential biomarkers of papillary thyroid carcinoma

Cited by 72 publications

References 23 publications

Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry

Serum proteome profiling of primary breast cancer indicates a specific biomarker profile

Contact Info

Product

Resources

About